March 26, 2020
National Cancer Center Japan
Nagoya Medical Center
Otsuka Pharmaceutical Co., Ltd.
Development of the first comprehensive genomic profiling assay for hematologic malignancies in Japan
- Consortium of major Japanese hospitals and Otsuka Pharmaceutical start a project to evaluate its clinical utility -
The National Cancer Center Japan (Tokyo) and Otsuka Pharmaceutical Co., Ltd. (Tokyo) have jointly developed a comprehensive genomic profiling assay for hematologic malignancies.
This assay covers almost all categories of hematologic malignancies: myeloid malignancies such as acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasm; lymphoid malignancies such as acute lymphoblastic leukemia, lymphoma, and myeloma; and congenital bone marrow failure syndromes. This assay will provide a valuable information for clinicians and patients in diagnosis, treatment, and prognostic prediction.
In the future, in order to facilitate the development of personalized medicine for blood cancers, the performance of this assay will be assessed at National Cancer Center Japan, Kyushu University (Fukuoka), Kyoto University (Kyoto), and Nagoya Medical Center (Aichi). Its feasibility and clinical utility will also be investigated at National Cancer Center Japan in a prospective clinical trial.
In this research project, Otsuka Pharmaceutical and major facilities in Japan will form a joint research consortium and work together.
Information in this news release was current as of the original release date.